Article Speculates AMAG Pharmaceuticals (AMAG) Could Be A Takeover Target

TheStreet.com's biotech guru, Adam Feuerstein, speculates that AMAG Pharmaceuticals (Nasdaq: AMAG) could be the target of a takeover, following last week's approval of Feraheme for intravenous use as an iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.

Feuerstein contends, ... the changing landscape for treatment of dialysis and pre-dialysis patients, especially the specter of Medicare dialysis bundling looming in the near future, also means that incumbent players in this market need to take big steps to ensure their future success.

According to Feuerstein, some potential suitors for AMAG includes Genzyme (Nasdaq: GENZ), Amgen (Nasdaq: AMGN), Johnson & Johnson (NYSE: JNJ) and Davita (NYSE: DVA).

You May Also Be Interested In

• Can Schneider do a deal for Bentley? Citi discusses
• Nordstrom family weighing taking retailer private - WSJ
• Blackstone (BX) Nears Deal to Sell Control of S.Korean Pharma Wholesaler Geo-young to MBK Parnters for Over $1B - Reuters